Page 22 - BH-2-2

Brain & Heart Oxidative stress and neurological disorders

doi: 10.1007/s11920-022-01326-3 98. Vejux A. Cell death, inflammation and oxidative stress in
neurodegenerative diseases: Mechanisms and cytoprotective
86. Tondo L, Vázquez GH, Baldessarini RJ. Depression
and Mania in bipolar disorder. Curr Neuropharmacol. molecules. Int J Mol Sci. 2021;22(24):13657.
2017;15(3):353-358. doi: 10.3390/ijms222413657
doi: 10.2174/1570159X14666160606210811 99. Niedzielska E, Smaga I, Gawlik M, et al. Oxidative
87. Harrison PJ, Geddes JR, Tunbridge EM. The emerging stress in neurodegenerative diseases. Mol Neurobiol.
neurobiology of bipolar disorder. Trends Neurosci. 2016;53(6):4094-4125.
2018;41(1):18-30. doi: 10.1007/s12035-015-9337-5
doi: 10.1016/j.tins.2017.10.006 100. Trist BG, Hare DJ, Double KL. Oxidative stress in the aging
88. Solé B, Jiménez E, Torrent C, et al. Cognitive impairment in substantia nigra and the etiology of Parkinson’s disease.
bipolar disorder: Treatment and prevention strategies. Int J Aging Cell. 2019;18(6):e13031.
Neuropsychopharmacol. 2017;20(8):670-680. doi: 10.1111/acel.13031
doi: 10.1093/ijnp/pyx032 101. Dias V, Junn E, Mouradian MM. The role of oxidative stress
89. Arnold I, Dehning J, Grunze A, Hausmann A. Old age in Parkinson’s disease. J Parkinsons Dis. 2013;3(4):461-491.
bipolar disorder-epidemiology, aetiology and treatment. doi: 10.3233/JPD-130230
Medicina (Kaunas). 2021;57(6):587.
102. Badanjak K, Fixemer S, Smajić S, Skupin A, Grünewald A.
doi: 10.3390/medicina57060587 The contribution of microglia to neuroinflammation in
90. McCormick U, Murray B, McNew B. Diagnosis and Parkinson’s disease. Int J Mol Sci. 2021;22(9):4676.
treatment of patients with bipolar disorder: A review doi: 10.3390/ijms22094676
for advanced practice nurses. J Am Assoc Nurse Pract.
2015;27(9):530-542. 103. Miyazaki I, Asanuma M. Neuron-astrocyte interactions in
Parkinson’s disease. Cells. 2020;9(12):2623.
doi: 10.1002/2327-6924.12275
doi: 10.3390/cells9122623
91. Kato T. Current understanding of bipolar disorder: Toward
integration of biological basis and treatment strategies. 104. Vrijsen S, Houdou M, Cascalho A, Eggermont J,
Psychiatry Clin Neurosci. 2019;73(9):526-540. Vangheluwe P. Polyamines in Parkinson’s disease:
Balancing between neurotoxicity and neuroprotection.
doi: 10.1111/pcn.12852
Annu Rev Biochem. 2023;92:435-464.
92. Post RM, Grunze H. The challenges of children with bipolar
disorder. Medicina (Kaunas). 2021;57(6):601. doi: 10.1146/annurev-biochem-071322-021330
doi: 10.3390/medicina57060601 105. Elsworth JD. Parkinson’s disease treatment: Past, present,
and future. J Neural Transm (Vienna). 2020;127(5):785-791.
93. Maron E, Nutt D. Biological markers of generalized anxiety
disorder. Dialogues Clin Neurosci. 2017;19(2):147-158. doi: 10.1007/s00702-020-02167-1
doi: 10.31887/DCNS.2017.19.2/dnutt 106. Gao C, Liu J, Tan Y, Chen S. Freezing of gait in Parkinson’s
disease: Pathophysiology, risk factors and treatments.
94. Locke AB, Kirst N, Shultz CG. Diagnosis and management Transl Neurodegener. 2020;9:12.
of generalized anxiety disorder and panic disorder in adults.
Am Fam Physician. 2015;91(9):617-624. doi: 10.1186/s40035-020-00191-5
95. Muris P, Ollendick TH. Selective mutism and its relations to 107. Pajares M, Rojo AI, Manda G, Boscá L, Cuadrado A.
social anxiety disorder and autism spectrum disorder. Clin Inflammation in Parkinson’s disease: Mechanisms and
Child Fam Psychol Rev. 2021;24(2):294-325. therapeutic implications. Cells. 2020;9(7):1687.
doi: 10.1007/s10567-020-00342-0 doi: 10.3390/cells9071687
96. Ströhle A, Gensichen J, Domschke K. The diagnosis 108. Sonntag KC, Song B, Lee N, et al. Pluripotent stem cell-
and treatment of anxiety disorders. Dtsch Arztebl Int. based therapy for Parkinson’s disease: Current status and
2018;155(37):611-620. future prospects. Prog Neurobiol. 2018;168:1-20.
doi: 10.3238/arztebl.2018.0611 doi: 10.1016/j.pneurobio.2018.04.005
97. Kaczkurkin AN, Foa EB. Cognitive-behavioral therapy for 109. Fabbri M, Barbosa R, Rascol O. Off-time treatment options
anxiety disorders: An update on the empirical evidence. for Parkinson’s disease [published correction appears in
Dialogues Clin Neurosci. 2015;17(3):337-346. Neurol Ther. 2023]. Neurol Ther. 2023;12(2):391-424.
doi: 10.31887/DCNS.2015.17.3/akaczkurkin doi: 10.1007/s40120-022-00435-8

Volume 2 Issue 2 (2024) 16 doi: 10.36922/bh.2704